NCT01113385 - Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Focal Segmental GlomerulosclerosisSteroid Resistant Nephrotic Syndrome

Interventions

DRUG

D-Galactose

Oral galactose will be initiated at a dose of 0.2gm/kg/dose twice daily to a maximum of 15 gm BID for a period of 4 months. The prescribed dose of D-galactose powder will be dispensed to subjects in packets, mixed with 4 ounces of water, and consumed orally.

Trial Locations (1)

20010

Children's National Medical Center, Washington D.C.